A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.

Détails

ID Serval
serval:BIB_E6692BB52E6C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Périodique
Nature cancer
Auteur⸱e⸱s
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D., Michel A., Mastroyannis S.A., Zsiros E., Dangaj Laniti D., Tsourti Z., Stevenson B.J., Iseli C., Levine B.L., Speiser D.E., Gfeller D., Bassani-Sternberg M., Powell D.J., June C.H., Dafni U., Kandalaft L.E., Harari A., Coukos G.
ISSN
2662-1347 (Electronic)
ISSN-L
2662-1347
Statut éditorial
Publié
Date de publication
10/2023
Peer-reviewed
Oui
Volume
4
Numéro
10
Pages
1410-1417
Langue
anglais
Notes
Publication types: Clinical Trial, Phase I ; Journal Article
Publication Status: ppublish
Résumé
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.
Mots-clé
Humans, Female, Ovarian Neoplasms/therapy, Vaccines, Adoptive Transfer, Vaccination, T-Lymphocytes
Pubmed
Création de la notice
25/09/2023 15:33
Dernière modification de la notice
09/12/2023 7:02
Données d'usage